Document:

Settlement Agreement dated September 19, 2003

 Exhibit 10.46 
  
 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN
THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
 EXECUTION COPY 
  
 SETTLEMENT AGREEMENT 
  
 This SETTLEMENT AGREEMENT (the “Settlement”) is made and entered into as of September 19,
2003 (the “Settlement Date”) by and between Kosan Biosciences Inc., a Delaware corporation having offices at 3832 Bay Center Place, Hayward, CA 94545 (“Kosan”) and the Sloan-Kettering Institute for Cancer Research, a non-profit
entity organized under the laws of the state of New York, and having its principal office at 1275 York Ave., New York, NY, 10021 (“Sloan-Kettering”). Kosan and Sloan-Kettering are sometimes referred to below each individually as a
“Party” and collectively as the “Parties.” 
  
 RECITALS 
  
 WHEREAS, Kosan and Sloan-Kettering are parties to a Research and License Agreement dated August 26, 2000 as amended by a Consent and Amendment effective September 16, 2002 (the agreement as so amended,
the “License Agreement”, and such consent and amendment, the “Consent”); 
  
 WHEREAS, a dispute has arisen between the Parties in relation to their respective rights and obligations under the License Agreement; 
  
 WHEREAS, Sloan-Kettering has taken the
position that certain compounds and patent filings are not licensed to Kosan under the License Agreement, but Kosan takes the position that these compounds and patent applications are licensed to Kosan under the License Agreement (part of the
Dispute, as more particularly defined below) and each Party has filed a complaint against the other Party in relation to the Dispute; and 
  
 WHEREAS, the Parties desire finally to compromise, settle and discharge all claims, controversies, demands, actions,
or causes of action which any Party to this Settlement may have or claim to have, now or in the future, against any other Party relating in any way to the Dispute (including without limitation by dismissing the complaints filed by the Parties in
relation to the Dispute prior to the Settlement Date). 
  
 NOW, THEREFORE, in consideration of the foregoing and the promises and mutual covenants and agreements herein contained, the Parties covenant and agree as follows: 
  
 AGREEMENT 
  
 ARTICLE 1 
  
 DEFINITIONS 
  
 All initially capitalized terms used but not defined in this Settlement have the meanings set forth in the License Agreement. References to
“Sections” are to the sections of this Settlement. In addition, the following initially capitalized terms shall have the following meanings: 
  
 1.1 “Consent” shall have the meaning given such term in the recitals. 
  

 1. 

 EXECUTION COPY 
  

 1.2 “Covered Period” shall mean the period from August 25, 2000 through the
Settlement Date. 
  
 1.3 “[*] Program” shall mean
all research and development work involving Epothilones or methods of manufacture or use of Epothilones (a) in the laboratory of [*] at Sloan-Kettering, (b) in the laboratory of [*] at Sloan-Kettering and/or (c) by any persons working under their
direction or in collaboration with them, in the case of each of (a), (b) and (c), during the Covered Period. 
  
 1.4 “Dispute” shall mean the Parties’ disagreement as to (a) which Epothilones are Collaboration Compounds under the License
Agreement; (b) whether the [*] Patents constitute SKI Patent Rights under the License Agreement; (c) whether all Epothilone-related research in the [*] laboratory or the [*] laboratory at Sloan-Kettering or in collaboration with either such
laboratory during the Covered Period constituted part of the Research Program; (d) whether any payments are due under Section 2.6 of the License Agreement in relation to the research described in clause (c) of this definition; (e) whether Kosan has
breached the License Agreement by failure to make any such payments described in clause (d); (f) whether Sloan-Kettering has the right to terminate the License Agreement on the basis of any alleged default or breach thereof by Kosan occurring prior
to the Settlement Date; and (g) any other aspect of either Party’s performance or non-performance under the License Agreement prior to the Settlement Date. 
  

1.5 “Epothilone D” shall mean the compound commonly referred to epothilone D, which has the following chemical structure: 

 
 [GRAPHIC] 
  
 1.6 “FDA” shall mean the United States Food and Drug
Administration. 
  
 1.7 “Filed Suits” shall mean
(a) the complaint filed by Sloan-Kettering against Kosan in the United States District Court for the Southern District of New York on June 4, 2003, and (b) the complaint filed by Kosan against Sloan-Kettering (or an affiliate thereof) in the United
States District Court for the Northern District of California on June 18, 2003. 
  

 2. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXECUTION COPY 
  

 1.8 “Kosan” shall have the meaning given such term in the first paragraph of this
document. 
  
 1.9 “License Agreement” shall have
the meaning given such term in the recitals. 
  
 1.10
“Party” and “Parties” shall have the meanings given such terms in the first paragraph of this document. 
  
 1.11 “Patent” shall mean any patent application or patent, of whatever kind or sort and however denominated or named, anywhere in the
world, whether filed on or before the Settlement Date or thereafter. 
  
 1.12 “Settlement” shall have the meaning given in the first paragraph of this document. 
  
 1.13 “Sloan-Kettering” shall have the meaning given such term in the first paragraph of this document. 
  
 1.14 “[*] Compound” shall mean a compound known as [*],
which has the following chemical structure: 
  
 [*] 
  
 1.15 “[*] Patents” shall mean (a) the patent applications
listed in Exhibit A; (b) all divisionals, continuations, continuations-in-part, and substitutions of any of the foregoing; (c) any other patent application claiming priority to any of the foregoing; (d) all patents issuing on any of the foregoing,
and all reissues, reexaminations, renewals and extensions thereof; and (e) all counterparts to any of the foregoing anywhere in the world. 
  
 1.16 “[*] Family” shall mean all Epothilones that [*] 
  
 ARTICLE 2 
  
 SUBSTANTIVE AGREEMENT 
  
 2.1 Dismissal of Complaints. The making of this Settlement does not in any way constitute an admission of liability or responsibility by any Party
to this Settlement. There is no prevailing party in either Filed Suit. Each Party shall bear its own fees and costs in relation to the Filed Suits. The Parties shall cause the Filed Suit in the Southern District of New York to be dismissed with
prejudice and without costs, and shall use best efforts to cause such dismissal to occur within three (3) business days after the Settlement Date. 
  
 2.2 Breaches Prior to the Settlement Date. The Parties acknowledge and agree that neither Party has or shall have the right to terminate the
License Agreement (in whole or in part) by reason of any alleged or actual breach thereof or default thereunder on or before the 

  

 3. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXECUTION COPY 
  

 
Settlement Date. Accordingly, the Parties are agreeing to the releases set forth in Sections 3.2 and 3.3. 
  
 2.3 Payments. 
  
 (a) Upfront. Kosan shall pay to Sloan-Kettering an
upfront payment totaling [*] (the “Upfront Payment”). This amount shall be payable in four (4) equal quarterly installments. The first such quarterly installment shall be payable within ten (10) business days after the Settlement
Date. Every three (3) months thereafter another such installment shall be due until Kosan has paid the total Upfront Payment. 
  
 (b) Milestones. Kosan shall pay to Sloan-Kettering the following milestone payments within thirty (30) days after first achievement
of the corresponding milestone event by or on behalf of Kosan or any Kosan sublicensee under the SKI Patent Rights: 
  

	 Milestone Event

	  	 Milestone Payment Amount

	 [*]
	  	[*]

  
 Each such milestone payment shall be
payable no more than once, regardless of whether the corresponding event is achieved multiple times with one or more compounds from the [*] Family. Each such milestone payment shall only be payable if the corresponding milestone event is
actually achieved. 
  
 (c) Relationship to
Other Payments. The payments provided for in this Section 2.3 are in addition to, not in lieu of, any possible payments under Articles 6 or 7 of the License Agreement (for clarity, as amended by the Consent). 
  
 2.4 Past Research Costs. Other than any amounts required to be paid in
accordance with Section 2.3, Kosan shall not owe any payment to Sloan-Kettering under the License Agreement, this Settlement or otherwise to support the [*] Program or Sloan-Kettering’s performance of its obligations under the Research Program
during the Covered Period (although Kosan shall remain responsible for possible future payments under Articles 6 or 7 of the License Agreement (for clarity, as amended by the Consent) if such work results in Products progressing through development
and commercialization). 
  
 2.5 Specific Understandings as to
Scope of Licensed Rights and Past Research Program. Sloan-Kettering and Kosan agree that the License Agreement means and shall be interpreted as follows: 
  

(a) [*] Family Compounds. All compounds within the [*] Family are and shall be Collaboration Compounds under the License
Agreement. Without limiting the general 

  

 4. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXECUTION COPY 
  

 
consequences of such status under the License Agreement, all compounds within the [*] Family are and shall be licensed to Kosan under Article 4 of the
License Agreement. 
  
 (b) [*]
Patents. All [*] Patents are and shall be SKI Patent Rights under the License Agreement. Without limiting the general consequences of such status under the License Agreement, all [*] Patents are and shall be licensed to Kosan under Article 4 of
the License Agreement, and all Epothilones claimed in them shall be Collaboration Compounds under the License Agreement licensed to Kosan under such Article of the License Agreement. 
  
 (c) Epothilone Research. The entire [*] Program was and shall be part of the Research Program
under the License Agreement. Consequently, all inventions conceived and/or reduced to practice pursuant to the [*] Program (including without limitation compositions of matter and methods of use and manufacture) that relate to any Epothilone or
method of making or using any Epothilone constitute inventions made by Sloan-Kettering in the performance of the Research Program, and all Patents claiming such inventions constitute SKI Patent Rights. Without limiting the general consequences of
the foregoing statuses, such Epothilones and Patents are and shall be licensed to Kosan pursuant to Article 4 of the License Agreement. 
  
 (d) Dominated Rights. All Patents owned or controlled by Sloan-Kettering now or in the future that claim an invention [*]
SKI Patent Rights (as SKI Patent Rights exist without regard to the remainder of this sentence) (such first group of Patents—[*] and [*]—the “Dominated Patents”), shall be deemed included in the SKI Patent Rights and licensed to
Kosan pursuant to Article 4 of the License Agreement. The Dominated Patents may include currently existing and future Patents, and may include Patents claiming inventions made outside of the [*] Program. 
  
 (e) Non-limitation. The foregoing subsections
(a) through (d) are intended to address specific aspects of the Dispute and specific categories of Epothilones and Patents that are included within the license to Kosan under Section 4.3 of the License Agreement, but such subsections are not
intended to limit the scope of the Collaboration Compounds and SKI Patent Rights. Other Epothilones and Patents may also be included in such categories, respectively (for example and without limitation, Epothilones claimed in any of the Patents
originally listed in Exhibit A to the License Agreement are also Collaboration Compounds). 
  
 2.6 Current Patent Filings. The Patents listed at Exhibit B (together with all other Patents related to them in the same way as Patents in Section 1.35(i) of the License Agreement relate to the Patents
listed in Exhibit B of the License Agreement when it was originally executed) are included (without limitation) in the SKI Patent Rights under the License Agreement. Exhibit B is intended to contain a complete list of all Patents filed by or on
behalf of Sloan-Kettering on or before the Settlement Date that relate to Epothilones and any methods of making or using them naming any inventor referred to in Section 1.3 (whether by name or descriptively), or otherwise included in the SKI Patent
Rights as of the Settlement Date. [*] that it has not assigned or otherwise conveyed to another entity Sloan-Kettering’s ownership interest in, nor granted any license under, any [*] Patent. If after the Settlement Date it is determined 

  

 5. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXECUTION COPY 
  

 
that any Patents described in the second sentence of this Section 2.4 were omitted from Exhibit B, such additional Patents shall be automatically included
within SKI Patent Rights, and Exhibit B shall be updated to include the omitted Patents. 
  
 2.7 Development Within the [*] Family. 
  
 (a) General. Kosan and its sublicensee under the SKI Patent Rights Roche are interested in evaluating compounds from the [*]
Family as candidates to be fast followers within the Kosan-Roche Epothilone development program (which development program currently is advancing Epothilone D into phase II clinical trials to treat cancer), with the goal, to the extent that any such
compounds are suitable, of promptly initiating scale-up work to produce sufficient quantities of one or more such compounds for Roche and/or Kosan to conduct IND-enabling studies thereof. Kosan shall devote reasonable efforts (itself or through a
sublicensee under the SKI Patent Rights) to the activities described in the foregoing sentence to attempt to identify a Phase I-Eligible Compound (as defined in subsection (b)). Whether or not Kosan and its sublicensee Roche succeed in identifying
an Epothilone within the [*] Family that is suitable for such further scale-up or qualifies as a Phase I-Eligible Compound (as defined in subsection (b)), Kosan (itself or through a sublicensee under the SKI Patent Rights) shall not be obligated to
expend more than [*] following the Settlement Date on efforts to do so (including without limitation any amounts either of them provides to Sloan-Kettering to support research at Sloan-Kettering and without regard to whether Kosan receives
government or other funding to cover any of the work by Kosan or otherwise). 
  
 (b) Obligation. If an Epothilone within the [*] Family tested by Kosan (or any Epothilone sublicensee of Kosan): 
  

[*] 
  
 (an Epothilone described by (i)-(v), a “[*]”), then, subject to [*] Kosan shall [*]. Such [*] shall be of a scope and [*] in [*] of [*], such as any one of the
[*] that Kosan has [*]. Kosan may satisfy its obligation under this Section 2.7(b) by the efforts of itself, Roche, any other Kosan sublicensee, any Kosan contractor, or any combination of the foregoing entities. 
  
 (c) Clarification. To avoid any doubt, Section
2.7(b) requires [*], and shall not be interpreted to [*] or a [*]. Also to avoid any doubt, if no compound within the [*] Family is determined to be a [*] then the [*] Family and the [*] Patents shall remain licensed to Kosan pursuant to the License
Agreement regardless of whether Kosan [*]. 
  
 (d) Timing. Prior to the [*] anniversary of the Settlement Date, provided that Kosan seeks to in good faith to identify a [*] (including without limitation through the efforts of its sublicensee under the SKI Patent
Rights), Kosan shall be in compliance with its obligations under this Section 2.7. The obligations of Kosan under this Section 2.7 shall expire if no compound within the [*] Family has been identified that is [*] by the [*] anniversary of the
Settlement Date. 
  

 6. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXECUTION COPY 
  

 (e) Remedy.  
  
 (i) If by the [*] anniversary of the Settlement Date
Kosan determines that it will not [*] any Epothilone within the [*] Family by such time, then Kosan shall notify Sloan-Kettering in writing. Kosan will state in its notice whether it has identified a [*]. 
  
 (ii) If Kosan identified an Epothilone within the [*]
Family that Kosan considers to be a [*], but notifies Sloan-Kettering that Kosan will not [*] any Epothilone within the [*] Family, then (1) the Epothilones within the [*] Family shall thereafter cease to be Collaboration Compounds licensed to Kosan
pursuant to the License Agreement, (2) if [*] any [*] any [*] under any [*] with respect to [*] then, [*] the [*] by Sloan-Kettering (or an affiliate thereof) [*] of [*] Kosan shall [*] all [*] to [*] pursuant to [*] pursuant to [*] (3) the
remainder of the Epothilones licensed to Kosan pursuant to the License Agreement shall continue to be Collaboration Compounds Licensed to Kosan thereunder, and (4) the License Agreement shall otherwise continue in full force and effect. 

 
 (iii) If the Parties disagree as to whether [*]
then the matter shall be resolved by conducting an arbitration in accordance with Section 2.9, in which the sole issue before the arbitrator shall be whether [*] by [*] that [*] within the [*] Family (by definition, an Epothilone of such family that
is described by all of 2.7(b)(i)-(v)) (such issue, the “Arbitration Issue”). If the arbitrator determines that [*], then each Party shall bear its own costs and Kosan shall retain its rights with respect to the [*] Patents and the
Epothilones of the [*] Family as described in Section 2.5 and shall be deemed to have fulfilled its diligence obligations hereunder. If the arbitrator determines that the [*] then either (1) Kosan shall within thirty (30) days thereafter [*] and
promptly thereafter initiate [*], or (2) if Kosan does not respond within thirty (30) days or declines to [*] then Section 2.7(e)(ii) shall apply, in its entirety. 
  
 (f) Further Development. The decision whether to proceed with any further or other [*] of any
Epothilones within the [*] Family beyond that required in subsection (b) shall, as between Kosan and Sloan-Kettering, be within Kosan’s sole discretion. Provided that Kosan has satisfied the requirements of subsection (b), regardless of whether
Kosan (or a sublicensee) proceeds with [*] of any Epothilone within the [*] Family beyond any that is required in subsection (b), all such Epothilones and the Patents claiming them shall remain licensed to Kosan under the License Agreement (again,
without limiting the scope of other Epothilones and Patents licensed to Kosan under the License Agreement). The obligation set forth in Section 2.7(b) is in lieu of any other diligence obligation with respect to the [*] Family express or implied, at
law or in equity.  
  
 2.8 Future Research
Program and Sloan-Kettering Role.  
  
 (a) Goal. The Parties recognize the important contribution that [*] and his research colleagues may be able to make in the development of the [*] Family, in particular in the area of making new Epothilones within the
[*] Family that may improve upon the properties of currently known such Epothilones. The Parties intend to resume a close collaboration 

  

 7. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXECUTION COPY 
  

 
promptly after the Settlement Date, in which there will be an open intellectual exchange and unified effort, and in which each Party will be able to focus
its efforts in its area of expertise. This may involve Kosan providing synthetic intermediates to [*] laboratory and conducting animal and other testing of new Epothilones invented in the [*] laboratory, in order to permit the [*] group to focus on
making novel Epothilones and making Epothilone synthesis process improvements, rather than synthesis of intermediates or toxicology and other IND-enabling work. The Parties recognize that a close collaboration as described in the foregoing sentences
is only possible under circumstances in which Kosan has rights to the fruits of the collaboration, and therefore wish to agree and make clear in this Settlement that such circumstances exist. 
  
 (b) Research Term. The Research Term under the
License Agreement shall continue (if later than it would otherwise expire) through at least [*] after the Settlement Date, or, if longer, for so long as [*] is collaborating with Kosan and/or Roche regarding Epothilone(s). 
  
 (c) Funding. The Parties recognize the value
of the opportunity for Sloan-Kettering researchers to continue their work in collaboration with Kosan and its sublicensee under the SKI Patent Rights, as well as the value of the synthetic intermediates and information that Kosan will be providing
for use in research at Sloan-Kettering. Kosan shall not owe any payment pursuant to the License Agreement, this Settlement or otherwise, to support research under the Research Program, Sloan-Kettering’s performance of its obligations
under the Research Program or the License Agreement, or any other Epothilone research conducted at Sloan-Kettering before or after the Research Term ends, except (i) to the extent that such research or performance is part of the Research Program
under the License Agreement and is budgeted in advance under a budget mutually agreed in writing by the Parties, or (ii) to the extent the Parties otherwise mutually agree in writing. Conversely, unless the Parties otherwise agree in writing,
Sloan-Kettering shall have no obligation to Kosan (or any Kosan sublicensee under the SKI/Patent Rights) to perform any Epothilone or other research that is not funded by Kosan (or its sublicensee). 
  
 (d) Other New Epothilones. If any Epothilone
research at Sloan-Kettering during the Research Term results in any Epothilone-related invention [*], then Kosan shall have the following rights with respect to Patents claiming such first invention (“Other Epothilone Patents”; all Other
Epothilone Patents claiming a common priority date shall be deemed to be a single Other Epothilone Patent and all divisionals, continuations, continuations-in-part, substitutions, reissues, extensions, supplementary protection certificates and other
applications based on a given patent filing that is an Other Epothilone Patent shall be deemed together to constitute a single Other Epothilone Patent): 
  
 (i) At any time prior to [*] the [*] or [*] the [*] included in [*] is [*] Kosan shall have the right, exercisable by written
notice to Sloan-Kettering and payment of a fee equal to [*] to include such Other Epothilone Patents among the SKI Patent Rights exclusively licensed to Kosan under the License Agreement and all Epothilones claimed (whether themselves or via a
method of manufacture or use thereof) by such Other Epothilone Patent (“Other Epothilones”) among the Collaboration Compounds exclusively licensed to Kosan under 

  

 8. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXECUTION COPY 
  

 
the License Agreement. Sloan-Kettering shall not negotiate with or entertain any offer from a Third Party regarding the terms upon which Sloan-Kettering
would grant the Third Party a license that would conflict with the license Kosan has the right to obtain under this paragraph prior to the expiration of Kosan’s right to obtain such license. 
  
 (ii) If Kosan does not exercise its right to obtain
such license prior to the expiration of Kosan’s right to obtain it with respect to any Other Epothilone Patent, and Sloan-Kettering wishes to grant a license under such Other Epothilone Patent with respect to any of such Other Epothilones, then
Sloan-Kettering shall notify Kosan in writing. If within [*] after Sloan-Kettering’s notice, Kosan notifies Sloan-Kettering in writing that Kosan wishes to negotiate the terms upon which Sloan-Kettering would grant Kosan such a license, then
Sloan-Kettering shall negotiate such terms exclusively with Kosan for a period of not less than [*] (the Parties’ negotiations of such terms, the “Negotiations”). 
  
 (iii) If the Parties do not reach written agreement as to such terms within such time period, then
Sloan-Kettering shall be free to discuss with any Third Party the terms upon which Sloan-Kettering would grant the Third Party a license under such Other Epothilone Patent for such Other Epothilones. 
  
 (iv) Prior to [*] Sloan-Kettering shall disclose to
Kosan in writing the [*] the [*] If requested in writing by Kosan within [*] after Sloan-Kettering provides Kosan with such written notice, Sloan-Kettering shall [*] [*] of [*]. If [*] then Sloan-Kettering shall be free [*] to execute an agreement
granting to the Third Party a license under such Other Epothilone Patents with respect to such Other Epothilones [*] of which [*] pursuant to this paragraph. 
  
 (v) [*] with respect to each Other Epothilone Patent, [*] Kosan’s rights under [*] with respect
to such Other Epothilone Patent. 
  
 (e)
Clarification Regarding Clinical Trials. The foregoing in this Section 2.8 shall not be interpreted so as to negate any written funding agreements (apart from the License Agreement) regarding clinical trials of Collaboration Compounds at
Sloan-Kettering that Kosan and Sloan-Kettering may have entered into on or before the Settlement Date, or that they may enter into thereafter. 
  
 2.9 Binding Arbitration of Future Controversies. The Parties shall resolve any future disputes among them regarding the Arbitration Issue
(defined in Section 2.7(e)(iii)) (such dispute, the “Controversy”) as follows: First, upon request of either Party, the JRC and/or JDAC for a period of thirty (30) days, and then an executive officer of Kosan and an executive officer of
Sloan-Kettering for a period of thirty (30) days (including face-to-face meetings of such executives if requested by either Party), shall discuss and seek to resolve the Controversy. If they fail to resolve the Controversy or either such executive
refuses to meet with the other, then either Party may refer the Controversy to binding arbitration by the filing of an arbitration demand setting forth a general description of the nature of the dispute and the nature and amount of damages and/or
other relief sought. 
  

 9. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXECUTION COPY 
  

 The binding arbitration shall be before either (a) an arbitrator selected by mutual agreement of the
Parties, or (b) if the Parties are unable to agree as to a single arbitrator, then each Party shall designate an arbitrator unaffiliated with either of them, and the Parties’ designated arbitrators shall select a third arbitrator who is
unaffiliated with either Party and is a retired judge or an attorney with at least fifteen (15) years experience in biotechnology or pharmaceutical licensing. The arbitrator of (a) or arbitrators of (b) is and are referred to hereafter as the
“Arbitrator”. The binding arbitration shall be conducted by specific rules and procedures (there being no preference for the rules established by JAMS, CPR, AAA or any other organized body and the Arbitrator instead being free to choose
among established rules and/or establish others) and on schedules selected by the Arbitrator after considering timely proposals that each Party shall submit by a deadline of no later than five (5) business days after either Party refers the
Controversy to the Arbitrator (by written notice to the non-referring party and the arbitrator), and consistent with the remainder of this Section 2.9. The Arbitrator’s guiding principle shall be to conduct an expeditious proceeding that
provides for appropriate discovery and an appropriate hearing. The standard for discovery shall be that the Parties be allowed such discovery as the Arbitrator determines is necessary or useful for the arbitration to constitute a fair and equitable
hearing. When in doubt, the Arbitrator shall favor the need for a fair proceeding over the need for an expedited proceeding. 
  
 The Arbitrator shall be authorized solely to determine the Arbitration Issue (defined in Section 2.7(e)(iii)), but shall NOT be authorized: (i) to award
compensatory damages, (ii) to award non-economic damages, such as for emotional distress, pain and suffering, or loss of consortium; (iii) to award punitive damages; or (iv) to reform, modify or materially change the License Agreement or this
Settlement or any other agreements contemplated hereunder. The Arbitrator also shall be authorized to grant any temporary, preliminary or permanent equitable remedy or relief he or she deems just and equitable and within the scope of this Agreement,
including, without limitation, an injunction or order for specific performance. The Arbitrator’s award shall be subject to challenge or appeal only in accordance with New York law regarding binding arbitration. The Arbitrator’s award may
be entered as a judgment in any court of competent jurisdiction. 
  
 Each party shall bear its own attorneys’ fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the Administrator and the Arbitrator. 
  

 10. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXECUTION COPY 
  

 ARTICLE 3 
  
 RELEASES; PROCEDURAL; MISCELLANEOUS 
  
 3.1 Publicity. The existence of the Dispute, the terms of this
Settlement and any information contained herein will remain confidential between the Parties hereto and their representatives and neither party shall disclose same to any person or entity (other than the officers, directors, attorneys, accountants,
auditors, insurers, and/or reinsurers of such Party under confidentiality) without the written consent of the other Party, except as follows: (i) in response to a judicial order compelling disclosure or as may otherwise be required by law or
Securities and Exchange Commission practice or requirement or be necessary to defend or assert claims by or against any Party hereto in a judicial proceeding; (ii) under confidentiality to a subsidiary, affiliate, associated, or parent company of
such Party and their counsel; (iii) under confidentiality to auditors of or counsel of such Party; and (iv) under confidentiality by Kosan to any sublicensee or prospective sublicensee it may have under SKI Patent Rights, or to parties conducting
due diligence with respect to a potential investment in or acquisition of Kosan. 
  
 3.2 Release. Except for the obligations of the Parties expressly set forth in this Settlement and any patent prosecution costs for prosecution of SKI Patent Rights (including without limitation of [*]
Patents) prior to the Settlement Date, each of the Parties and their respective successors and assigns, and all of their respective servants, agents, directors, officers, members, managers, employees and attorneys, release each other of and from any
and all Claims arising from the Dispute, or from the Parties’ performance under, non-performance or default under, or breach of, the License Agreement in each case on or before the Settlement Date (collectively, the “Released
Claims”). Each of the foregoing entities (other than the Parties) is a third-party beneficiary of this Settlement. 
  
 3.3 General Release. The Parties understand and agree that this is a full, complete and final general release of any and all Released
Claims, and each Party agrees that it shall apply to all unknown, unanticipated, unsuspected and undisclosed Released Claims, as well as those which are now known, anticipated, suspected or disclosed. Each Party has been fully advised by its
respective attorney of the contents of section 1542 of the Civil Code of the State of California, and that section and the benefits thereof are hereby expressly waived, along with those under any similar or equivalent laws in other jurisdictions.
Such Section 1542 reads as follows: 
  
 “Section 1542. (General Release-Claims Extinguished.) A general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must
have materially affected his settlement with the debtor.” 
  
 3.4 No Other Representations. The terms of this Settlement are contractual and not a mere recital. This Settlement is executed without reliance upon any promise, warranty or representation by any Party other than those
expressly contained herein. This Settlement may not be modified except by an agreement in writing signed by both Parties. This Settlement sets 

  

 11. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXECUTION COPY 
  

 
forth the Parties’ entire agreement with respect to the Dispute, and there are no other representations, warranties, agreements or understanding between
the Parties with respect to the Dispute that are not set forth in this Agreement. 
  
 3.5 Assignment. This Settlement shall bind the heirs, personal representatives, successors and permitted assigns of each Party and inure to the benefit of each Party and each of their respective
successors and permitted assigns. Neither Party may assign this Settlement in whole or in part except that either Party may assign this Agreement along with the License Agreement in making a permitted assignment under the License Agreement.

  
 3.6 Expenses. Each Party to this Settlement will
bear its own costs, expenses, and attorney’s fees, whether taxable or otherwise, incurred in or arising out of or in any way related to the matters released herein, except as is otherwise specifically provided herein. 
  
 3.7 No Draftsmanship Implication. This Settlement has been
negotiated among the Parties and their respective legal counsel, and any legal or equitable principles that might require the construction of this Settlement or any provision of this Settlement against the Party drafting this Settlement will not
apply in any construction or interpretation of this Settlement. 
  
 3.8 Miscellany. Sections 21.3 – 21.8, 21.14 and 21.15 of the License Agreement shall apply to this Settlement as if set forth herein in their entireties. 
  

 12. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXECUTION COPY 
  

 IN WITNESS WHEREOF, the Parties have duly authorized and caused this Settlement to be executed
on the dates indicated below. 
  

	KOSAN BIOSCIENCES INC.	 	 	 	THE SLOAN-KETTERING INSTITUTE FOR CANCER
RESEARCH
					
	By:	 	 /s/ Robert G. Johnson, Jr.
	 	 	 	By:	 	 /s/ James S. Quirk

	 	
	 	 	 	 	

	 Name: 
	 	 Robert G. Johnson, Jr.
	 	 	 	 Name: 
	 	 James S. Quirk

	 	
	 	 	 	 	

	 Title:
	 	Sr. V.P. Medical Affairs &
Corp. Dev.	 	 	 	 Title:
	 	 Senior Vice President
 Research Resources Management

	 	
	 	 	 	 	

					
	 Date:
	 	 September 18, 2003
	 	 	 	 Date:
	 	 9/24/03

	 	
	 	 	 	 	

  

 13. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

EXECUTION COPY 
  

 EXHIBIT A 
 [*] PATENTS 
  

	 Filing Date

	  	 Serial No.

	  	 Kosan Docket #

	  	 Country

	  	 Sloan -Kettering Ref. #

	 [*]
	  	[*]	  	[*]                 [*][*]	  	[*]	  	[*]

  

 1. 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

EXECUTION COPY 
  

 EXHIBIT B 
 COMPLETE (AS REPRESENTED BY SKI) LISTING OF SKI PATENT RIGHTS
AS OF SETTLEMENT DATE 
  

	 Filing Date

	  	 Serial No.

	  	 Kosan Docket #

	  	 Country

	  	 Sloan -Kettering Ref. #

	 [*]
	  	[*]	  	[*]                 [*][*]	  	[*]	  	[*]

  

 1.DEVELOPMENT AND SUPPLY AGREEMENT

 Exhibit 10.1 
  
 DEVELOPMENT AND SUPPLY AGREEMENT 
  
 This AGREEMENT is made and entered into this 20th day of August, 2003 (the “Effective Date”) by and between
Sigma-Aldrich Fine Chemicals, a division of Sigma-Aldrich, Inc. having a principal place of business at 3050 Spruce Street, St. Louis, Missouri 63103, (“SAFC”) and GlycoGenesys, Inc., having a principal place of business at 31 St. James
Avenue, Boston, Massachusetts 02116 (“Client”). Both SAFC and Client are referred to herein individually as “Party” and collectively as the “Parties.” 
  
 WITNESSETH THAT: 
  
 WHEREAS, SAFC has expertise, personnel, the facility for, and experience in manufacturing components for pharmaceutical products and is willing to provide
such services to client companies in the pharmaceutical area and; 
  
 WHEREAS, Client has a commercial interest in the manufacture of the Product as hereafter defined and requests the services of SAFC in the manufacturing of such Product pursuant to the Project Charter and SAFC desires to manufacture such
Product on behalf of Client pursuant to such Project Charter and in accordance with the terms and conditions contained herein; 
  
 NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements contained herein, the Parties agree as follows: 
  
 ARTICLE 1 
 DEFINITIONS 
  

	1.	 	As used in this Agreement, the following definitions shall apply: 

  

	 	1.1	 	“Act” shall mean the U.S. Food, Drug and Cosmetic Act of 1934, the Public Health Service Act of 1944 and the regulations promulgated thereunder, as the same may be amended
from time to time. 

  

	 	1.2	 	“Active Pharmaceutical Ingredient” or “API” shall mean the active pharmaceutical ingredient of the Product. 

  

	 	1.3	 	“Affiliate” shall mean any corporation or non-corporate business entity, which directly or indirectly controls, is controlled by, or is under common control with a Party.
A corporation or non-corporate business entity shall be regarded as in control of another corporation if it owns or directly or indirectly controls at least fifty percent (50%) of the voting stock of the other corporation or (a) in the absence of
the ownership of at least fifty percent (50%) of the voting stock of a corporation or (b) in the case of a non-corporate entity, the power to direct or cause the direction of the management and policies of such corporation or non-corporate entity,
as applicable. 

  

	 	1.4	 	“Batch” or “Lot” shall mean, with respect to Product, each separate and distinct quantity of Product processed under continuous conditions and designated by a
batch or lot number. 

  

	 	1.5	 	“cGMP Regulations” means Current Good Manufacturing Practices as defined from time to time under the Act, as codified in 21 CFR Parts 210 and 211 and being currently
utilized within the pharmaceutical industry to manufacture the applicable type of Product(s). 

  

	 	1.6	 	“Certificate of Analysis” or “COA” shall mean a document certifying a Batch or Lot of Product meets all established and mutually agreed upon Specifications as
referenced, signed and dated by a duly authorized representative of the Quality Control or Quality Assurance Department of SAFC or Client as the case may be. 

  

 1 

	 	1.7	 	“Confidential Information” shall mean any nonpublic information of SAFC or Client that will be communicated to the other Party including without limitation, trade secrets,
business methods, operating procedures, manufacturing methods and processes, prices, and customer information, whether of a written, oral, visual or electronic nature, including but not limited to any such nonpublic information that may have been
disclosed between the SAFC and Client f/k/a SafeScience, Inc. from the date of that certain Confidential Disclosure Agreement dated April 15, 1999, as amended through and including the term of this Agreement. 

  

	 	1.8	 	“FDA” shall mean the United States Food and Drug Administration. 

  

	 	1.9	 	“Intellectual Property” shall mean property that can be protected under federal law, including copyrightable works, ideas, discoveries, and inventions.

  

	 	1.10	 	“Product” shall mean Sigma Product No. G7665—GCS-100 Liquid Bulk Intermediate. 

  

	 	1.11	 	“Project Charter” shall mean a written document or documents as agreed to by the Parties, describing the activities required to develop and manufacture the Product. The
Project Charter will be consolidated within a single attachment in Exhibit A to this Agreement. 

  

	 	1.12	 	“Quality Agreement” shall mean a written document, mutually agreed to by the Parties, describing the obligations of the Parties with regards to compliance, quality
systems, and testing and release of the Product. The Quality Agreement will be attached as Exhibit B to this Agreement. 

  

	 	1.13	 	“Regulatory Authority” shall mean any federal, state, local, or international regulatory agency, department, bureau, or other governmental agency having jurisdiction over
the manufacture, sale, or distribution of Product, including but not limited to the Canadian Health Protection Branch, the European Medicines Evaluation Agency, the U.S. Food and Drug Administration, and “Regulatory Authorities” shall mean
collectively all such regulatory authorities. 

  

	 	1.14	 	“Specially Regulated Waste” shall mean any Product refuse, remainder, residue, waste water or other discard material, including solid, liquid, semisolid, or contained
gaseous material that arises from the manufacture of the Product(s) which may be subject to or require special handling, treatment, storage, or disposal under any federal, state or local laws or regulations. 

  

	 	1.15	 	“Specifications” shall mean (1) the performance parameters for which Product, ingredients and packaging components must comply to be considered acceptable and (2) the
written record of such Product performance parameters annexed hereto within the applicable Project Charter attachment. Specifications may be amended from time to time by written agreement of the Parties. 

  

	 	1.16	 	“Client’s Technology Package” shall mean such technical information to be supplied by Client to SAFC to enable SAFC to carry out its obligations hereunder. Items
which may be included in the Technology Package include, but is not limited to, Client’s raw material and manufacturing component specifications, intermediate and product specifications, analytical and microbiological method validation reports,
analytical method transfer protocols, filter validation reports, raw material, intermediate and product storage specifications. 

  

	 	1.17	 	“Third Party” shall mean any party other than Client or SAFC and their respective affiliates. 

  

 2 

 ARTICLE 2 
 PRODUCT DEVELOPMENT 
  

	2.	 	The Parties agree to the following provisions regarding Product Development: 

  

	 	2.1	 	Client and SAFC shall jointly prepare and agree to in writing a Project Charter document, which may be amended from time to time as defined herein, for the Product, which shall, at
a minimum, incorporate the following: 

  

	 	2.1.1	 	the Product development schedule; 

  

	 	2.1.2	 	the stages in which the Project Charter is to be carried out (if any) and whether the commencement of each stage is dependent on successful completion of the previous stage;

  

	 	2.1.3	 	identify the facilities, staffing, supplies, and equipment required for the Project Charter and who (Client or SAFC) is responsible for providing each of such items;

  

	 	2.1.4	 	identify which Party is responsible for performing the various tasks or stages of the Project Charter; 

  

	 	2.1.5	 	Specifications as defined in Section 1.15; 

  

	 	2.1.6	 	a set of objective criteria whereby it can be assessed whether the Project Charter (and any stages thereof) has achieved its objectives; 

  

	 	2.1.7	 	identify all documents (Client’s Technology Package) and the timeline for delivery of such documents by Client to SAFC. 

  

	 	2.1.8	 	identify all documents (including regulatory documents) and other deliverables to be provided by SAFC to Client; and 

  

	 	2.1.9	 	a good faith estimate of the number of Batches or Lots required to complete the Project Charter. 

  

	 	2.1.10	 	define Project Charter prices; and 

  

	 	2.1.11	 	define Project Charter payment schedule in accordance with applicable milestones. 

  

	 	2.2	 	SAFC shall respond in a timely manner to Client’s inquiries regarding the status of any Project Charter. 

  

	 	2.3	 	SAFC and Client may from time to time negotiate in good faith changes to any Project Charter: 

  

	 	2.3.1	 	If such changes require SAFC to perform additional work or repeat work outside the original scope of the project, and such additional work is not required due to SAFC’s fault
or negligence, SAFC and Client shall negotiate in good faith the price and timing for such additional work. 

  

	 	2.4	 	Each Party shall provide the other Party, in a timely fashion, with all relevant information, documentation, and data necessary or appropriate for the Parties’ performance
hereunder. Except as explicitly otherwise provided in this Agreement, in the event a Party is to review or approve any information, documentation, data, or other materials supplied by the other Party, such review or approval shall be completed
within five (5) business days, unless additional time is requested based on a reasonable explanation provided within five (5) business days of the initial request. 

  

	 	2.5	 	Each Party shall use its commercially reasonable best efforts to successfully complete the Project Charter. However, the Parties agree and understand that neither Party hereto
guarantees that the project will be successful or conducted in accordance with the project timetable nor warrants nor guarantees that a marketable product will result from the project. 

  

 3 

	 	2.6	 	SAFC shall have the right to review those portions of Client’s proposed regulatory submissions relating to SAFC’s facilities or procedures before the submissions are filed
with Regulatory Authorities. SAFC shall complete its review of such submissions within ten (10) business days after receipt. SAFC shall consult with and advise Client in responding to questions from Regulatory Authorities regarding regulatory
submissions for the Product. 

  

	 	2.7	 	Right of Negotiation to Manufacture: Subject to right which may be granted by Client to third parties in connection with collaborative development and marketing arrangements, prior
to commencing negotiations with any third party regarding the commercial manufacture of the Product, Client shall commence good faith negotiations regarding the same with SAFC. 

  
 ARTICLE 3 
 INTELLECTUAL PROPERTY RIGHTS 
  

	3.	 	The Parties agree to the following provisions regarding Intellectual Property Rights: 

  

	 	3.1	 	Ownership: The Parties agree that: (a) Client shall retain all of its ownership rights in and to Client’s Intellectual Property, (b) SAFC shall retain all of its ownership
rights in and to SAFC’s Intellectual Property; (c) Client shall own all inventions made or conceived solely by Client; (d) SAFC shall own any inventions made or conceived solely by SAFC without utilizing the Confidential Information of
GlycoGenesys, and (e) Client shall own any inventions made or conceived jointly by the Parties in connection with the performance of this Agreement or by SAFC utilizing the Confidential Information of GlycoGenesys. 

  

	 	3.2	 	License Grants: Client hereby grants to SAFC a nonexclusive, worldwide, royalty-free license during the term of this Agreement to use such Client Intellectual Property rights as are
necessary for SAFC to perform SAFC’s obligations under this Agreement. SAFC hereby grants to Client a nonexclusive, worldwide, royalty-free, perpetual license to practice any inventions made or conceived solely by SAFC and incorporated into the
manufacturing or packaging processes associated with the Product. 

  

	 	3.3	 	Limitation on Use: Except as expressly stated in this Agreement, no Intellectual Property rights of any kind or nature are conveyed by this Agreement and neither Party shall have
any right, title or interest in or to the other Party’s Intellectual Property rights for any purpose whatsoever without such other Party’s prior written consent. Upon termination of this Agreement for whatever reason, neither Party shall
use or exploit in any manner whatsoever any Intellectual Property rights or nature belonging solely to the other Party. 

  
 ARTICLE 4 
 EQUIPMENT PRICE

  

	4.	 	The Parties agree to the following provisions regarding equipment price: 

  

	 	4.1	 	Client shall pay for the price of equipment specifically purchased for the processing of Product including the price for purchasing and installing the equipment, as well as any and
all maintenance costs associated with such equipment subject to Client’s prior approval of such prices, which shall not be unreasonably withheld. Currently, SAFC is in possession of certain pectin dispensing equipment at its manufacturing site
which is owned by and utilized solely for the benefit of Client for the processing of the Product herein. 

  

 4 

	 	4.2	 	Client shall own equipment paid for by Client pursuant to Section 4.1. Client shall have the right to file such UCC filings as necessary to establish ownership of such equipment.
SAFC may purchase such equipment at the termination of this Agreement at the fair market value of such equipment at that time as mutually agreed by the Parties. 

  

	 	4.3	 	Any price associated with the removal of equipment and to return the facility in serviceable condition shall be borne by Client. 

  
 ARTICLE 5 
 REPRESENTATIONS AND WARRANTIES 
  

	5.	 	The Parties agree to the following representations and warranties: 

  

	 	5.1	 	The Parties represent and warrant to the other as follows: 

  

	 	5.1.1	 	It has full power and authority to enter into this Agreement and consummate the transactions contemplated hereby and that the terms of this Agreement are not inconsistent with other
contractual obligations, expressed or implied, by which it is bound. 

  

	 	5.1.2	 	It has such permits, licenses, and authorizations of government or regulatory authorities as are necessary to own its respective properties, conduct its business and consummate the
transactions contemplated hereby, provided however, that Client shall be solely responsible for obtaining all permits, licenses, and authorizations for SAFC to process and ship Product(s), except for securing approval of SAFC’s facility as a
registered FDA facility, which shall be the responsibility of SAFC. 

  

	 	5.1.3	 	It is not currently under investigation for disbarment action, debarred, suspended, or otherwise excluded by the FDA or other Regulatory Authority from conducting business.

  

	 	5.1.4	 	All laboratory, scientific, technical and/or other data submitted by or on behalf of Client or SAFC, as the case may be, relating to Product(s) shall, to the best of their
knowledge, be true and correct and shall not contain any material falsification, misrepresentation or omission. 

  

	 	5.2	 	SAFC represents and warrants to Client as follows: 

  

	 	5.2.1	 	Product(s) shall be processed in compliance with the Quality Agreement and all applicable laws. 

  

	 	5.2.2	 	Product(s), as processed and delivered, shall comply with specifications and shall not be adulterated or misbranded within the meaning of the Act or other substantially similar laws
and statutes, provided however that the foregoing shall not apply to the extent that any such breach is caused by any materials provided by Client or due to compliance with any specifications or instructions provided by Client.

  

	 	5.2.3	 	The manufacturing facilities for Product(s) shall conform, and will throughout the term of this Agreement, in all respects to applicable laws, regulations, and approvals governing
such facility, including, but not limited to, the cGMP’s as defined by 21 Code of Federal Regulation Sections 210, 211, et seq., and will be adequate to produce the quantities of Product(s) as detailed in the Project Charter(s). SAFC
shall implement such requirements as may be necessary to comply with The Control of Substance Hazardous to Health (COSHH) Regulations of 1988, consolidated in 1994, amended in 1996, 1997 and 1998 and further consolidated in 1999 in connection with
the performance of its obligations under this Agreement. 

  

 5 

	 	5.2.4	 	Neither it nor any person employed by it or to be employed by it to perform the Project Charter(s) (i) is presently under any obligation which conflicts with their duties
contemplated hereunder and agrees not to undertake any project which will conflict with these duties during the conduct of the Project Charter(s) or (ii) has a disqualification hearing pending or has been disqualified by the FDA pursuant to 21
C.F.R. Section 312.70 or the European Union equivalent. In the event any of the foregoing occurs, SAFC shall immediately notify Client. 

  

	 	5.3	 	Client represents and warrants to SAFC as follows: 

  

	 	5.3.1	 	Client has the full power and authority to grant the license it grants under this Agreement and neither the granting of such license nor the exercise by SAFC of the rights granted
by Client under such license breaches any obligation to or right of any Third Party. 

  

	 	5.3.2	 	Neither the Client’s Product technology, nor the use thereof by SAFC, shall infringe, violate nor misappropriate any patent, copyright, trademark, trade secret or other
intellectual property of any Third Party. 

  

	 	5.3.3	 	Any excipients, API’s or other materials provided by Client to SAFC shall comply with specifications and shall not be adulterated or misbranded within the meaning of the Act or
other substantially similar laws and statutes. 

  

	 	5.3.4	 	Client will disclose to SAFC any information currently known or learned subsequent to the execution of this Agreement regarding toxicity, or other known health or environmental
hazards or other safe handling requirements for the API or Product(s) as the case may be. 

  

	 	5.4	 	THE WARRANTIES SET FORTH HEREIN ARE THE SOLE AND EXCLUSIVE WARRANTIES MADE BY EITHER PARTY UNDER THIS AGREEMENT, AND NEITHER PARTY MAKES ANY OTHER WARRANTIES EXPRESS OR IMPLIED OR
ARISING BY LAW, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTY ARISING FROM THE COURSE OF PERFORMANCE, COURSE OF DEALING OR USAGE OF TRADE. 

  

	 	5.5	 	EXCEPT FOR THE INDEMNITY OBLIGATIONS SET FORTH IN THIS AGREEMENT AND IN THE EVENT OF A BREACH OF THE CONFIDENTIALITY OBLIGATIONS SET FORTH IN THIS AGREEMENT, UNDER NO CIRCUMSTANCES
WILL EITHER PARTY BE LIABLE TO THE OTHER UNDER ANY CONTRACT, TORT, STRICT LIABILITY, NEGLIGENCE OR OTHER LEGAL OR EQUITABLE THEORY, FOR COVER OF ANY INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR LOST PROFITS IN CONNECTION WITH THE SUBJECT MATTER
OF THIS AGREEMENT INCLUDING WITHOUT LIMITATION THE PRODUCT(S) OR ANY SERVICES PROVIDED IN CONNECTION WITH THE PRODUCT(S) EXCEPT FOR THE INDEMNITY OBLIGATIONS SET FORTH IN THIS AGREEMENT. 

  
 ARTICLE 6 
 NONCONFORMING PRODUCT 
  

	6.	 	In the event of Client finding the quality of Product(s) is/are not acceptable in terms of Specifications, Client shall have thirty (30) calendar days from the date of its receipt
of the Product(s) to notify SAFC, specifying the respects in which the Product(s) is/are not acceptable. In the event that SAFC shall dispute any such determination by Client, the Parties shall use their best efforts to resolve the dispute amicably.
If the Parties are unable to do so, the matter shall be referred to an independent laboratory or consultant, mutually agreed to by both Parties, who’s decision shall be final and binding. The Party against whom the dispute is decided shall pay
for any charges for such laboratory or consultant. SAFC’s liability will be limited to replacement of the Product provided Client. 

  

 6 

 ARTICLE 7 
 PRICE – PAYMENT 
  

	7.	 	The Parties agree to the following price and payment provisions: 

  

	 	7.1	 	The price to be paid by Client for the Project Charter shall be defined in the Project Charter Documents as such may be amended to this Agreement from time to time.

  

	 	7.2	 	SAFC shall submit invoices to Client reflecting the work completed in accordance with the applicable milestones described in the applicable Project Charter documents. The invoices
shall be sent to the following address: 

  

	 	 	 GlycoGenesys, Inc.,
 Attention: Accounts
Payable
 31 St. James Avenue
 Boston, Massachusetts
02116
	 	 

  

	 	7.3	 	All payments due hereunder to SAFC shall be sent to SAFC by wire transfer of funds via the Federal Reserve Wire Transfer System to: 

  

	 	 	 Sigma-Aldrich, Inc.
 C/O Wachovia Bank,
N.A.
 P.O. Box 932594
 Atlanta, GA 31193-2594
 Account # 
 ABA# 
	 	 

  
 Client shall make any and all payments in accordance with the Project Charter described in Exhibit A hereto. 
  

	 	7.4	 	All prices for Product shall be on the basis of Product being shipped F.O.B. St. Louis, Missouri to Client’s plant in Spokane, Washington, under “Freight Collect”
terms. Shipment of Product(s) shall be arranged by Client, and the price and liability of such shipment borne by Client. 

  
 ARTICLE 8 
 CONFIDENTIALITY

  

	8.	 	In carrying out Project Charter(s) it is recognized by SAFC and Client that each may have to disclose to the other Confidential Information. Since both Parties wish to assume that
Confidential Information is properly protected they hereby agree as follows: 

  

	 	8.1	 	Form of Disclosure: Confidential Information may be disclosed in either oral, written or electronic form. 

  

	 	.	 	        The receiving Party’s duties under this Agreement shall apply only to Confidential Information that is: (a) disclosed by the
disclosing Party in writing and marked to indicate it is confidential at the time of disclosure; or (b) disclosed by the disclosing Party in any other manner and indicated to be confidential at the time of disclosure and thereafter is summarized in
a written memorandum, marked to indicate it is confidential and delivered to receiving Party within thirty (30) days of disclosure; or (c) disclosed in the form of tangible products or materials transmitted to the receiving Party with an
accompanying written memorandum. 

  

	 	8.2	 	Obligations: The receiving Party agrees to hold Confidential Information in strict confidence and to use it only for the purposes under this Agreement. The receiving Party agrees
not to disclose the Confidential Information to any Third Party unless prior written authorization has been obtained from the disclosing Party. These obligations shall not apply to: 

  

	 	8.2.1	 	Information which, at the time of disclosure, is in the public domain. 

  

 7 

	 	8.2.2	 	Information which, after disclosure, becomes part of the public domain by publication or otherwise, except by breach of this Agreement by the receiving Party.

  

	 	8.2.3	 	Information which the receiving Party can demonstrate by its written records was in the receiving Party’s possession at the time of the disclosure, and which was not acquired
directly or indirectly, from the disclosing Party. 

  

	 	8.2.4	 	Information which is lawfully disclosed to the receiving Party on a non-confidential basis by a Third Party who is not obligated to the disclosing Party or any other Third Party to
retain such information in confidence. 

  

	 	8.2.5	 	Information which results from research and development by the receiving Party independent of such disclosure as shown by competent evidence. 

  

	 	8.2.6	 	Information which is required to be disclosed by legal process, but only that portion of Information which is legally required to be disclosed; provided, in each case the Party so
required to disclose such Information informs the other Party as promptly as practicable in order to enable the other Party to seek a protective order or other appropriate remedy. The Party required to disclose such Information shall use its best
efforts to limit the disclosure and maintain confidentiality to the extent possible. The Party required to disclose such Information shall give the other Party written notice of any Confidential Information disclosed pursuant to this Section 8.2.6.

  

	 	8.3	 	Both Parties covenant and agree that they have and shall maintain an appropriate internal program limiting the internal distribution of Confidential Information to those of its
Affiliates, subsidiaries, officers, servants, or agents who require said Confidential Information so that either Party may use Confidential Information for the purpose set forth in this Agreement. The Parties may disclose each other’s
Confidential Information to third-party consultants but only to the extent that they require access to Confidential Information in order to enable each other to carry out the purpose of this Agreement. The Parties covenant and agree that before
making any Confidential Information available to said Affiliates, subsidiaries, officers, servants, agents, or third-party consultants, they shall inform such parties of the confidential nature of such information and obtain their agreement to be
bound by obligations of confidentiality and non-use which are equivalent to or greater than those set forth in this Agreement. The receiving Party agrees to promptly notify the disclosing Party in writing if it becomes aware of a breach of this
Article 8 by it or any party to whom it disclosed Confidential Information pursuant to this Section 8.3. 

  

	 	8.4	 	The receiving Party hereby acknowledges that disclosure or use of Confidential Information may result in irreparable harm to the disclosing Party. Accordingly, the receiving Party
agrees that the disclosing Party shall have the right to seek equitable relief, including without limitation an injunction or temporary restraining order, in the event of any actual or threatened breach of this Article 8. 

 

	 	8.5	 	Upon the written request of the disclosing Party, Confidential Information in tangible or electronic form received by the receiving Party from the disclosing Party shall, at the
disclosing Party’s sole option and expenses either be destroyed or immediately returned and the receiving Party shall provide written certification that all copies of Confidential Information have been destroyed or returned; provided, however
the receiving Party may maintain a single copy of the Confidential Information and its work product containing Confidential Information solely for the purposes of monitoring or demonstrating its compliance with this Agreement or applicable laws or
regulations. 

  

	 	8.6	 	The obligations and duties of nondisclosure under Article 8 shall survive the termination or expiration of this Agreement for a period of five (5) years thereafter.

  
  

 8 

 ARTICLE 9 
 INDEMNIFICATION 
  

	9.	 	The Parties agree to the following Indemnification clauses: 

  

	 	9.1	 	Indemnification by Client: Client shall indemnify, defend and hold SAFC, its Affiliates and their respective directors, officers, employees, agents, successors and assigns harmless
from and against any damages, judgements, claims, suits, actions, liabilities, costs and expenses (including, but not limited to, reasonable attorneys’ fees) resulting from any Third Party claims or suits arising solely out of (1) the use,
handling, distribution, marketing or sale of the Product(s) except to the extent caused by SAFC’s negligent acts or omissions or willful misconduct in its performance of the Project Charter(s) or the manufacture or bulk packaging of the
Product(s), (2) Client’s uncured material breach of any of its warranties or representations hereunder, or (3) Client’s grossly negligent acts or omissions or willful misconduct. 

  

	 	9.2	 	Indemnification by SAFC: Except as otherwise provided in Section 9.1 above, SAFC shall indemnify, defend and hold Client, its Affiliates and their respective directors, officers,
employees, agents, successors and assigns harmless from and against any damages, judgements, claims, suits, actions, liabilities, costs and expenses (including, but not limited to, reasonable attorneys’ fees) resulting from any Third Party
claims or suits arising solely out of (1) SAFC’s material breach of any of its warranties or representations hereunder or (2) SAFC’s grossly negligent acts or omissions or willful misconduct in its performance of the Project Charter(s) or
the manufacture or bulk packaging of the Intermediate(s) and Product(s). 

  

	 	9.3	 	Indemnification Procedures: 

  

	 	9.3.1	 	Any Party hereto seeking indemnification hereunder (in this context the “Indemnified Party”) shall notify the other Party (in this context the “Indemnifying
Party”) in writing reasonably promptly after the assertion against the Indemnified Party any claim or suit by a Third Party (a “Third Party Claim”) in respect of which the Indemnified Party intends to base a claim for indemnification
hereunder. 

  

	 	9.3.2	 	(1) The Indemnifying Party shall have the right, upon written notice given to the Indemnified Party within thirty (30) calendar days after receipt of the notice from the Indemnified
Party of any Third Party Claim, to assume the defense and handling of such Third Party Claim, at the Indemnifying Party’s sole expense, in which case the provisions of Section 9.3.2 (2) below shall govern. (2) The Indemnifying Party shall
select counsel reasonably acceptable to the Indemnified Party in connection with conducting the defense and handling of such Third Party Claim, and the Indemnifying Party shall defend or handle the same in consultation with the Indemnified Party,
and shall keep the Indemnified Party appraised of the status of the Third Party Claim. The Indemnifying Party shall not, without the prior written consent of the Indemnified Party, which consent will not be unreasonably withheld, agree to a
settlement of any Third Party Claim that could directly or indirectly lead to liability or create any financial or other obligation on the part of the Indemnified Party for which the Indemnified Party is not entitled to indemnification hereunder.
The Indemnified Party shall cooperate with the Indemnifying Party and shall be entitled to participate in the defense or handling of such Third Party Claim with its own counsel at its own expense. 

  
  

 9 

	 	9.3.3	 	(1) If the Indemnifying Party does not give written notice to the Indemnified Party, within thirty (30) calendar days after receipt of the notice from the Indemnified Party of any
Third Party Claim, of the Indemnifying Party’s election to assume the defense or handling of such Third Party Claim, the provisions of Section 9.3.3 (2) below shall govern. (2) The Indemnified Party may, at the Indemnifying Party’s
expense, select counsel in connection with conducting the defense or handling of such Third Party Claim and defend or handle such Third Party Claim in such manner as it may deem appropriate, provided, however, that the Indemnified Party shall keep
the Indemnifying Party timely appraised of the status of such Third Party Claim and shall not settle such Third Party Claim without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably withheld. If the
Indemnified Party defends or handles such Third Party Claim, the Indemnifying Party shall cooperate with the Indemnified Party and shall be entitled to participate in the defense or handling of such Third Party Claim with its own counsel and at its
own expense. 

  

	 	9.3.4	 	If the Indemnified Party intends to seek indemnification hereunder, other than for a Third Party Claim, then it shall notify the Indemnifying Party in writing within three (3)
months after its discovery of facts upon which it intends to base its Claim for indemnification hereunder; provided, however, the failure to timely give such notice shall limit the Indemnifying Party’s liability for indemnification only to the
extent the Indemnifying Party’s defense of such matter has been prejudiced. 

  

	 	9.3.5	 	Except with regard to fraud or pursuant to Section 8.4, the indemnification remedies in this Article 9, enforced in accordance with Section 9.3, shall constitute the sole and
exclusive remedies of the Parties with respect to any matters arising under or relating to this Agreement. 

  

	 	9.4	 	Survival of Indemnification Obligations: The provisions of this Article 9 shall survive the expiration or termination of this Agreement for a period of five (5) years.

  

	 	9.5	 	Limitation of Liability and Claims: Neither Party shall be liable to the other Party for indirect, special, punitive, or consequential damages of any kind, including without
limitation lost profits or loss of good will or otherwise. Neither Party’s liability to the other under this Agreement shall exceed Five Million Dollars ($5,000,000). 

  

	 	9.6	 	Insurance: Both Client and SAFC shall obtain and maintain, either itself or through one or more of its affiliates, with reputable carriers, product liability insurance with limits
of not less than Five Million Dollars ($5,000,000) per claim/annual aggregate by no later than the scheduled manufacturing date for the first Batch of Product(s) delivered as part of the first Project Charter(s) conducted under this Agreement. In
addition, SAFC shall maintain commercial general liability insurance including premises and operations coverage of not less than $1,000,000 per occurrence and $2,000,000 per accident and will endeavor to provide property damages liability insurance
of not less than $1,000,000 per occurrence and $1,000,000 per accident. Each Party hereto shall have its insurance carrier(s) furnish the other Party hereto with a certificate that such insurance is in force. In the event of any proposed
cancellation, non-renewal, or material adverse change in such coverage, the other Party hereto shall be given at least thirty (30) calendar day’s advance written notice thereof. 

  
 ARTICLE 10 
 TERM AND TERMINATION 
  

	10.	 	The Parties agree to the following Term and Termination clauses: 

  

	 	10.1	 	Term: This Agreement shall remain in full force and effect for a period of six (6) months from the Effective Date herein or as otherwise agreed to by the parties in writing.

  

	 	10.2	 	Termination by Mutual Agreement: This Agreement may be terminated, at any time upon mutual written agreement between the Parties. 

  
  

 10 

	 	10.3	 	Termination for Default: This Agreement may be terminated by either Party in the event of material breach or default by the other Party of the terms and conditions hereof; provided,
however, the other Party shall first give to the defaulting Party written notice of the proposed termination or cancellation of this Agreement, specifying the grounds therefor. Upon receipt of such notice, with respect to such defaults as are
capable of being cured, the defaulting Party shall have forty-five (45) calendar days to respond by curing such default. If the breaching Party does not respond or fails to work diligently to cure such breach within the additional time set forth
above, then the other Party may either suspend the Agreement indefinitely or terminate the Agreement. Termination of this Agreement pursuant to this Section 10.3 shall not affect any other rights or remedies which may be available to the
nondefaulting Party. 

  

	 	10.4	 	Bankruptcy; Insolvency: 

  

	 	10.4.1	 	Either Party may terminate this Agreement upon the occurrence of any of the following with respect to the other Party: 

  

	 	10.4.1.1	 	The entry of a decree or order for the relief by a court having jurisdiction in the premises in respect of such other Party in an Involuntary case under the Federal Bankruptcy Code,
as now constituted or hereafter amended, or any other applicable federal or state insolvency or other similar law and the continuance of any such decree or order unstayed and in effect for a period of sixty (60) consecutive calendar days;

  

	 	10.4.1.2	 	The filing of such other Party of a petition for relief under the Federal Bankruptcy Code, as now constituted or hereafter amended, or by any other applicable federal or state
insolvency or other similar law, or; 

  

	 	10.4.1.3	 	The failure of such other Party to pay its debts when due. 

  

	 	10.4.2	 	SAFC shall notify Client of its intent to file for protection under the Federal Bankruptcy Code as soon as such a determination is made. SAFC will segregate all Client-related
documents, including, but not limited to, manufacturing and analytical equipment protocols, qualifications, procedures, methods, calibrations reports and/or certificates, Specifications, Manufacturing Procedures, Intermediate and Product analytical
data, SAFC facility documentation in support of Project Charters; all Client provided manufacturing and analytical testing equipment, including any equipment purchased by Client for SAFC in conjunction with the Project Charter; all unconsumed raw
materials provided by Client to SAFC in conjunction with the Project Charter; and all Product Batches, that were produced in accordance with the Project Charter. SAFC will provide Client complete and total access to these materials at Client’s
request. 

  

	 	10.5	 	Rights and Duties Upon Termination: 

  

	 	10.5.1	 	Upon termination of this Agreement, SAFC shall, promptly as practicable, cease work on the Project Charter and turn over to Client one (1) copy of all results, documentation and
information obtained during the Project Charter (whether in written or electronic form) and all Product Batches, as well as all unconsumed raw materials provided by Client which are then in SAFC’s possession and which are the property of Client
in accordance with this Agreement. 

  

	 	10.5.2	 	Upon termination of this Agreement, Client shall remain liable for all fees, expenses, and uncancellable obligations incurred hereunder through the date of such termination.

  
  

 11 

 ARTICLE 11 
 FORCE MAJEURE/DISPUTE RESOLUTION 
  

	11.	 	The Parties agree to the following Force Majeure/Dispute Resolution clauses: 

  

	 	11.1	 	Effect of Force Majeure: Neither Party shall be held liable or responsible for any loss or damages resulting from any failure or delay in its performance due hereunder (other than
payment of money) caused by force majeure. As used herein, force majeure shall be deemed to include any condition beyond the reasonable control of the affected Party including, without limitation, war, riot, earthquake, tornado, hurricane, flood or
other natural disasters, fire, civil disorder, explosion, accident, sabotage, lack of or inability to obtain adequate fuel, power, materials, labor, containers, transportation, supplies or equipment, compliance with governmental requests, laws,
rules, regulations, orders or actions; inability despite best efforts to renew operating permits or licenses from local, state or federal governmental authorities; breakage or failure of machinery or apparatus; national defense requirements; or
supplier strike, lockout or injunction. SAFC shall notify Client of any foreseeable force majeure events, including, but not limited to, shipping interruptions or problems, and inability to procure supplies necessary for SAFC to perform any of its
obligations under this Agreement. 

  

	 	11.2	 	Notice of Force Majeure: In the event either Party is delayed or rendered unable to perform due to force majeure, the affected Party shall give notice of the same and its expected
duration to the other Party promptly after the occurrence of the cause relied upon, and upon the giving of such notice the obligations of the Party giving the notice will be suspended during the continuance of the force majeure; provided, however,
such Party shall take commercially reasonable steps to remedy or mitigate the force majeure with all reasonable dispatch. 

  

	 	11.3	 	Dispute Resolution: The Parties hereto agree to perform the terms of this Agreement in good faith, and to attempt to resolve any controversy, dispute or claim arising hereunder in
good faith. Any dispute regarding the validity, construction, interpretation, or performance of this Agreement (other than provisions, hereof relating to any intellectual property rights, or the confidentiality obligations contained in Article 8
hereof) shall be (1) first attempted to be resolved between the CEO/President of each Party and failing that (2) submitted to binding arbitration in Seattle, Washington, U.S.A. to be conducted in accordance with the Arbitration Rules of the American
Arbitration Association (“AAA”); provided, however, that nothing in this Section 11.3 shall be construed to preclude either Party from seeking provisional remedies, including, but not limited to, temporary restraining orders and
preliminary injunctions, from any court of competent jurisdiction, in order to protect its rights pending arbitration, but such preliminary relief shall not be sought as a means of avoiding arbitration. Any arbitration hereunder shall be submitted
to an arbitration tribunal made up of three (3) members, one of whom shall be selected by Client, one of whom shall be selected by SAFC, and one of whom shall be selected by the other two arbitrators. All arbitration proceedings shall be conducted
in English. The order or award of the arbitrators shall be final and may be enforced in any court of competent jurisdiction. The prevailing Party in any legal or arbitration action brought by one Party against the other Party shall be entitled, in
addition to any other rights and remedies it may have, to reimbursement for its expenses incurred thereby, including court cost and reasonable attorney’s fees. The Parties shall have the right of limited prehearing discovery, including:

  

	 	11.3.1	 	exchange of witness lists; 

  

	 	11.3.2	 	exchange of documentary evidence and reasonably related documents; 

  

	 	11.3.3	 	written interrogations; and 

  

	 	11.3.4	 	subject to reasonable discretion of the arbitrators and upon good cause shown dispositions under oath of any witnesses who are to be called to testify at the arbitration hearing.

  

	 	11.4	 	As soon as the discovery is concluded, the arbitrators shall hold a hearing in accordance with the aforesaid AAA rules. 

  

 12 

 ARTICLE 12 
 NOTICES 
  

	12.	 	All notices provided herein shall be in writing and shall be deemed to be delivered when deposited in the United States mail, postage prepaid, or hand-delivered to an authorized
representative of the Party to whom notice is directed, or sent by facsimile, or express service courier, charges prepaid, to the address of the other Party designated below: 

  

	 Client
  
 GlycoGenesys, Inc.
 31 St. James
Avenue
 Boston, MA 02116
 Attention: Mark Staples
 FAX: (617) 422-0675
	 	 SAFC
  
 Sigma-Aldrich Fine Chemicals,
 a division of
Sigma-Aldrich, Inc.
 3050 Spruce Street,
 St. Louis, Missouri 63103
 Attention: Paula L. Rehkemper
 Fax: 314-286-8005

  
 The addresses and
persons provided above may be changed by either Party by providing the other Party with written notice of such change. 
  
 ARTICLE 13 
 MISCELLANEOUS

  

	13.	 	The Parties agree to the following Miscellaneous clauses: 

  

	 	13.1	 	Entire Agreement: This Agreement, attachments and exhibits contain the entire understanding between the Parties with respect to the subject matter hereof, and may be modified, only
by a written instrument duly executed by each Party’s authorized representative. 

  

	 	13.2	 	Independent Contractor: Nothing herein shall create any equity association, partnership, joint venture, or ownership relation of principal and agent between the parties hereto, it
being understood that Client is purchasing SAFC services as an independent company, and neither Party shall have the authority to bind the other party or the other’s representatives in any way. 

  

	 	13.3	 	Publicity: Except as explicitly set forth below in Section 13.4, any press release, publicity or other form of public written disclosure related to this Agreement prepared by one
Party shall be submitted to the other party prior to release for written approval, which approval shall not be unreasonably withheld or delayed by such other Party. 

  

	 	13.4	 	Use of Party’s Name: Except as expressly provided or contemplated hereunder and except as otherwise required by applicable law, no right is granted pursuant to this Agreement
to either Party to use in any manner the trademarks or name of the other Party, or any other trade name, service mark, or trademark owned by or licensed to the other Party in connection with the performance of the Agreement. To the extent required
by applicable law, the Parties shall be permitted to use the other Party’s name and disclose the existence and terms of this Agreement in connection with required public regulatory fillings, public securities filings and private placement
memoranda and documentation, using reasonable commercial efforts to protect the confidentiality of the terms of this Agreement. 

  
  

 13 

	 	13.5	 	Severability: Each Party hereby expressly agrees that it has no intention to violate any public policy, statutory or common laws, rules, regulations, treaty or decision of any
government agency or executive body of any country or community or association of countries; that if any word, sentence, paragraph, clause or combination thereof in this Agreement is found by a court or executive body with judicial powers having
jurisdiction other this Agreement or either Party hereto, in a final unappealed order, to be in violation of any such provisions in any country or community or association of countries, such words, sentences, paragraphs, clauses or combination shall
be inoperative in such country or community or association of countries and the remainder of this Agreement shall remain binding upon the Parties, so long as enforcement of the remainder does not violate the Parties’ overall intentions in this
transaction. 

  

	 	13.6	 	Assignment; Subcontractors: This Agreement may not be assigned or otherwise transferred by either Party without the prior written consent of the other Party; provided, however,
either Party may, without such consent, assign this Agreement. 

  

	 	13.6.1	 	in connection with the transfer or sale of all or substantially all of the assets or voting securities of such Party or the line of business of which this Agreement forms a part,

  

	 	13.6.2	 	in the event of a merger or consolidation of a Party hereto with another company or to any Affiliate of the assigning Party fully capable of performing hereunder.

  
 Any purported assignment in violation of the
proceeding shall be void. Any permitted assignee shall assume all obligations of its assignor under this Agreement. No assignment shall relieve either Party of responsibility for the performance of any obligation which accrued prior to the effective
date of such assignment. 
  

	 	13.7	 	Governing Law: This Agreement shall be governed by and construed in accordance with the laws of the state of Missouri, irrespective of any conflicts of law rule which may direct or
refer such determination of applicable law to any other state; and if this Agreement were performed wholly within the state of Missouri. 

  

	 	13.8	 	Headings: Paragraph headings and captions used herein are for convenience of reference only and shall not be used in the construction or interpretation of this Agreement.

  

	 	13.9	 	Continuing Obligations: Termination, assignment or expiration of this Agreement shall not relieve either Party from full performance of any obligations incurred prior thereto.

  

	 	13.10	 	Waiver: Neither Party’s waiver of any breach or failure to enforce any of the terms and conditions of this Agreement, at any time, shall not in any way affect, limit or waive
such Party’s right thereafter to enforce and compel strict compliance with every term and condition of this Agreement. 

  

	 	13.11	 	Construction: This Agreement has been jointly prepared on the basis of the mutual understanding of the Parties and shall not be construed against either Party by reason of such
Party’s being the drafter hereof or thereof. 

  

	 	13.12	 	Exhibits, Schedules and Attachments: Any and all exhibits, schedules and attachments referred to herein form an integral part of this Agreement and are incorporated into this
Agreement by such reference. 

  

	 	13.13	 	Specially Regulated Waste: The prices associated with the removal of Specially Regulated Waste shall be borne by Client. Client will be notified of the determination of Specially
Regulated Waste and advised of the price for destruction of said waste. 

  

 14 

 IN WITNESS WHEREOF, this Agreement has been executed by the Parties as of the day and year first written above.

  

	FOR: SAFC	 	FOR: GLYCOGENESYS, INC.
		
	 /s/ David Feldker

 Signature
	 	 /s/ Mark Staples

 Signature

		
	 David Feldker

 Printed Name
	 	 Mark A. Staples, MBA, Ph.D.

 Printed Name

		
	 Vice President

 Title
	 	 VP Development and Manufacturing

 Title

		
	 Aug. 22, 2003

 Date Signed
	 	 Aug. 21, 2003

 Date Signed

  

 15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}]]